Silo Wellness Announces LOI to Acquire NUGL/Kaya in a Transaction Valued at CAD $43,289,624.60; CSE to Halt Trading Until Shareholder Approval | Psychedelic Invest

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it has retained the services of Clarivate™, a leading global provider of information services including IP lifecycle management solutions. Under terms of the agreement, Clarivate will manage, maintain, and track the Company’s intellectual property assets and…

ADA Advises Against Compounded GLP-1s; Growth Hormone Therapy Guide; T1D Outcomes Up

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and dual GIP/GIP-1 receptor agonists for type 2 diabetes or obesity

December 4, 2024

It’s happy hour (for now) for Alnylam

Good morning and happy Wednesday. Today we’re talking about insulin, pharma’s ties with politicians, and some nice champagne. The need-to-know this morning Roche shares traded

July 17, 2024

Wegovy can reduce heart failure symptoms in obese patients, study shows – Pharmaceutical Technology

The results from a global Phase III trial funded by Novo Nordisk found significant symptom improvement in patients with preserved ejection fraction (HFpEF). Image credit:

August 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.